Thermo Fisher Scientific (NYSE:TMO) Sets New 52-Week High – Should You Buy?

Thermo Fisher Scientific Inc. (NYSE:TMO)’s share price hit a new 52-week high during mid-day trading on Wednesday. The company traded as high as $683.32 and last traded at $680.0990, with a volume of 711022 shares traded. The stock had previously closed at $679.61.

Wall Street Analyst Weigh In

A number of research firms have commented on TMO. Stifel Nicolaus set a $650.00 price objective on shares of Thermo Fisher Scientific in a research note on Wednesday, August 5th. Morgan Stanley boosted their price target on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Wall Street Zen cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, September 12th. Citigroup downgraded Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a report on Wednesday, September 9th. Finally, UBS Group raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $540.00 to $730.00 in a research note on Tuesday, September 8th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $628.78.

Thermo Fisher Scientific Trading Down 3.4%

The firm has a market capitalization of $241.17 billion, a price-to-earnings ratio of 35.09, a price-to-earnings-growth ratio of 2.82 and a beta of 0.87. The company has a fifty day moving average price of $616.86 and a 200-day moving average price of $533.86. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion for the quarter, compared to analyst estimates of $11.71 billion. During the same quarter last year, the firm earned $4.28 earnings per share. The company’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities research analysts predict that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

Insider Activity at Thermo Fisher Scientific

In other news, EVP Michael Shafer sold 25,500 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the sale, the executive vice president owned 20,994 shares in the company, valued at approximately $12,596,400. This represents a 54.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc Casper sold 10,000 shares of the stock in a transaction dated Thursday, August 20th. The shares were sold at an average price of $629.27, for a total value of $6,292,700.00. Following the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $77,982,284.75. This represents a 7.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 73,768 shares of company stock valued at $44,122,820. Insiders own 0.33% of the company’s stock.

Hedge Funds Weigh In On Thermo Fisher Scientific

A number of institutional investors have recently made changes to their positions in TMO. Tsfg LLC boosted its holdings in Thermo Fisher Scientific by 20.4% during the second quarter. Tsfg LLC now owns 112 shares of the medical research company’s stock worth $56,000 after buying an additional 19 shares in the last quarter. Renasant Bank boosted its stake in shares of Thermo Fisher Scientific by 1.0% during the 2nd quarter. Renasant Bank now owns 1,934 shares of the medical research company’s stock worth $970,000 after acquiring an additional 20 shares in the last quarter. TCI Wealth Advisors Inc. grew its holdings in shares of Thermo Fisher Scientific by 5.4% in the 1st quarter. TCI Wealth Advisors Inc. now owns 431 shares of the medical research company’s stock worth $212,000 after acquiring an additional 22 shares during the period. Legacy Wealth Managment LLC ID raised its holdings in Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after purchasing an additional 22 shares during the last quarter. Finally, Chesapeake Wealth Management boosted its position in Thermo Fisher Scientific by 0.6% during the second quarter. Chesapeake Wealth Management now owns 3,725 shares of the medical research company’s stock worth $1,868,000 after purchasing an additional 22 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.